CA2160878A1 - Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique - Google Patents
Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression geniqueInfo
- Publication number
- CA2160878A1 CA2160878A1 CA002160878A CA2160878A CA2160878A1 CA 2160878 A1 CA2160878 A1 CA 2160878A1 CA 002160878 A CA002160878 A CA 002160878A CA 2160878 A CA2160878 A CA 2160878A CA 2160878 A1 CA2160878 A1 CA 2160878A1
- Authority
- CA
- Canada
- Prior art keywords
- nucleic acid
- acid
- dna
- poly
- microparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormones [GH] (Somatotropin)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4753693A | 1993-04-19 | 1993-04-19 | |
US08/047,536 | 1993-04-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2160878A1 true CA2160878A1 (fr) | 1994-10-27 |
Family
ID=21949539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002160878A Abandoned CA2160878A1 (fr) | 1993-04-19 | 1994-04-19 | Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0696200A4 (fr) |
JP (1) | JPH08510639A (fr) |
AU (1) | AU6707194A (fr) |
CA (1) | CA2160878A1 (fr) |
NZ (1) | NZ265818A (fr) |
WO (1) | WO1994023738A1 (fr) |
Families Citing this family (76)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69310339T2 (de) | 1993-02-19 | 1997-08-21 | Howard Green | Präparate, die Corneozyt Proteine enthalten |
US6348449B1 (en) | 1993-09-21 | 2002-02-19 | The Trustees Of The University Of Pennsylvania | Methods of inducing mucosal immunity |
US6551618B2 (en) * | 1994-03-15 | 2003-04-22 | University Of Birmingham | Compositions and methods for delivery of agents for neuronal regeneration and survival |
EP0804249A2 (fr) | 1994-03-15 | 1997-11-05 | Brown University Research Foundation | Systeme de liberation de genes polymeres |
AUPM747694A0 (en) * | 1994-08-16 | 1994-09-08 | Commonwealth Scientific And Industrial Research Organisation | Delivery of nucleic acids and peptides |
US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
EP0840623B1 (fr) * | 1995-07-21 | 2007-07-18 | Brown University Research Foundation | Compositions pour la thérapie génétique contenant des microparticules polymères chargées d'un acide nucléique |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
US6270795B1 (en) | 1995-11-09 | 2001-08-07 | Microbiological Research Authority | Method of making microencapsulated DNA for vaccination and gene therapy |
AU717113B2 (en) * | 1995-11-09 | 2000-03-16 | Health Protection Agency | Microencapsulated DNA for vaccination and gene therapy |
GB9709900D0 (en) * | 1997-05-15 | 1997-07-09 | Microbiological Res Authority | Microencapsulated DNA for vaccination and gene therapy |
US20020165183A1 (en) * | 1999-11-29 | 2002-11-07 | Hans Herweijer | Methods for genetic immunization |
GB9619002D0 (en) * | 1996-09-11 | 1996-10-23 | Oxford Biosciences Ltd | Particle delivery |
US6893664B1 (en) * | 1996-06-17 | 2005-05-17 | Powderject Research Limited | Particle delivery techniques |
US6228624B1 (en) | 1996-08-02 | 2001-05-08 | Immunivest Corporation | Method to select and transfect cell subpopulations |
DE59707744D1 (de) * | 1996-10-23 | 2002-08-22 | Sueddeutsche Kalkstickstoff | Verfahren zur herstellung von biologisch aktiven polymernanopartikel-nucleinsäure-konjugaten |
DK1005374T3 (da) * | 1997-01-22 | 2007-08-20 | Mgi Pharma Biolog Inc | Mikropartikler til fremföring af nukleinsyre |
US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
CA2792122C (fr) | 1997-07-07 | 2015-09-08 | Medical Research Council | Procede de selection in vitro |
IT1293088B1 (it) * | 1997-07-10 | 1999-02-11 | Isi Ist Sierovaccinogeno Ital | Microparticelle per il rilascio controllato di molecole biologicamente attive e loro uso in terapia, profilassi e diagnostica in vitro e in |
US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
US6475994B2 (en) * | 1998-01-07 | 2002-11-05 | Donald A. Tomalia | Method and articles for transfection of genetic material |
WO1999036570A2 (fr) | 1998-01-20 | 1999-07-22 | Pericor Science Inc | Liaison d'agents au tissu par transglutaminase |
AU3291099A (en) * | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Genetic vaccine vector engineering |
US6328967B1 (en) | 1998-03-12 | 2001-12-11 | Allergenics, Inc. | Delivery system to modulate immune response |
US6395253B2 (en) * | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
GB9810236D0 (en) | 1998-05-13 | 1998-07-08 | Microbiological Res Authority | Improvements relating to encapsulation of bioactive agents |
US6406719B1 (en) | 1998-05-13 | 2002-06-18 | Microbiological Research Authority | Encapsulation of bioactive agents |
WO1999058656A2 (fr) * | 1998-05-13 | 1999-11-18 | The Regents Of The University Of Michigan | Liberation prolongee d'adn depuis des matrices structurales |
WO1999065531A1 (fr) * | 1998-06-18 | 1999-12-23 | Johns Hopkins University School Of Medicine | Methodes et reactifs d'administration intramusculaire d'acides nucleiques |
US6818626B1 (en) * | 1998-07-17 | 2004-11-16 | Mirus Corporation | Chelating systems for use in the delivery of compounds to cells |
US6916490B1 (en) | 1998-07-23 | 2005-07-12 | UAB Research Center | Controlled release of bioactive substances |
NZ510928A (en) * | 1998-10-01 | 2002-10-25 | Powderject Res Ltd | Spray coated powder composition formed from seed particles between 10-100 micrometres coated with an aqueous pharmaceutical composition |
CA2276066A1 (fr) * | 1999-03-11 | 2000-09-11 | Zycos Inc. | Microparticules pour diffusion d'un acide nucleique |
AU4173000A (en) | 1999-03-19 | 2000-10-09 | Regents Of The University Of Michigan, The | Mineralization and cellular patterning on biomaterial surfaces |
US6767928B1 (en) | 1999-03-19 | 2004-07-27 | The Regents Of The University Of Michigan | Mineralization and biological modification of biomaterial surfaces |
US7776321B2 (en) | 2001-09-26 | 2010-08-17 | Mayo Foundation For Medical Education And Research | Mutable vaccines |
GB0127564D0 (en) * | 2001-11-16 | 2002-01-09 | Medical Res Council | Emulsion compositions |
US20050085434A1 (en) * | 2002-01-25 | 2005-04-21 | Catchpole Ian R. | Dna dosage forms |
GB0201736D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | DNA dosage forms |
US20040048260A1 (en) * | 2002-09-10 | 2004-03-11 | Fu-Hsiung Chang | Transfection of nucleic acid |
EP2261372B1 (fr) | 2003-01-29 | 2012-08-22 | 454 Life Sciences Corporation | Procédé d'amplification et de séquençage d'acides nucléiques |
US20060078893A1 (en) | 2004-10-12 | 2006-04-13 | Medical Research Council | Compartmentalised combinatorial chemistry by microfluidic control |
GB0307428D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Compartmentalised combinatorial chemistry |
GB0307403D0 (en) | 2003-03-31 | 2003-05-07 | Medical Res Council | Selection by compartmentalised screening |
WO2005010145A2 (fr) | 2003-07-05 | 2005-02-03 | The Johns Hopkins University | Procede et compositions de detection et d'enumeration de variations genetiques |
US20050221339A1 (en) | 2004-03-31 | 2005-10-06 | Medical Research Council Harvard University | Compartmentalised screening by microfluidic control |
US7968287B2 (en) | 2004-10-08 | 2011-06-28 | Medical Research Council Harvard University | In vitro evolution in microfluidic systems |
WO2007081385A2 (fr) | 2006-01-11 | 2007-07-19 | Raindance Technologies, Inc. | Dispositifs microfluidiques et leurs procédés d'utilisation dans la formation et le contrôle de nanoréacteurs |
GB0602637D0 (en) | 2006-02-09 | 2006-03-22 | Glaxo Group Ltd | Novel process |
EP2530168B1 (fr) | 2006-05-11 | 2015-09-16 | Raindance Technologies, Inc. | Dispositifs microfluidiques |
US9074242B2 (en) | 2010-02-12 | 2015-07-07 | Raindance Technologies, Inc. | Digital analyte analysis |
US9562837B2 (en) | 2006-05-11 | 2017-02-07 | Raindance Technologies, Inc. | Systems for handling microfludic droplets |
US9012390B2 (en) | 2006-08-07 | 2015-04-21 | Raindance Technologies, Inc. | Fluorocarbon emulsion stabilizing surfactants |
US8772046B2 (en) | 2007-02-06 | 2014-07-08 | Brandeis University | Manipulation of fluids and reactions in microfluidic systems |
US8592221B2 (en) | 2007-04-19 | 2013-11-26 | Brandeis University | Manipulation of fluids, fluid components and reactions in microfluidic systems |
EP4047367A1 (fr) | 2008-07-18 | 2022-08-24 | Bio-Rad Laboratories, Inc. | Procedé de détection d'analytes cibles au moyens des bibliothèques de gouttelettes |
EP3415235A1 (fr) | 2009-03-23 | 2018-12-19 | Raindance Technologies Inc. | Manipulation de gouttelettes microfluidiques |
WO2011042564A1 (fr) | 2009-10-09 | 2011-04-14 | Universite De Strasbourg | Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations |
EP2517025B1 (fr) | 2009-12-23 | 2019-11-27 | Bio-Rad Laboratories, Inc. | Procédés pour réduire l'échange de molécules entre des gouttelettes |
US10351905B2 (en) | 2010-02-12 | 2019-07-16 | Bio-Rad Laboratories, Inc. | Digital analyte analysis |
US9399797B2 (en) | 2010-02-12 | 2016-07-26 | Raindance Technologies, Inc. | Digital analyte analysis |
US9366632B2 (en) | 2010-02-12 | 2016-06-14 | Raindance Technologies, Inc. | Digital analyte analysis |
WO2012045012A2 (fr) | 2010-09-30 | 2012-04-05 | Raindance Technologies, Inc. | Dosages sandwich dans des gouttelettes |
EP3412778A1 (fr) | 2011-02-11 | 2018-12-12 | Raindance Technologies, Inc. | Procédés permettant de former des gouttelettes mélangées |
WO2012112804A1 (fr) | 2011-02-18 | 2012-08-23 | Raindance Technoligies, Inc. | Compositions et méthodes de marquage moléculaire |
WO2012167142A2 (fr) | 2011-06-02 | 2012-12-06 | Raindance Technolgies, Inc. | Quantification d'enzyme |
US8841071B2 (en) | 2011-06-02 | 2014-09-23 | Raindance Technologies, Inc. | Sample multiplexing |
US8658430B2 (en) | 2011-07-20 | 2014-02-25 | Raindance Technologies, Inc. | Manipulating droplet size |
US11901041B2 (en) | 2013-10-04 | 2024-02-13 | Bio-Rad Laboratories, Inc. | Digital analysis of nucleic acid modification |
US9944977B2 (en) | 2013-12-12 | 2018-04-17 | Raindance Technologies, Inc. | Distinguishing rare variations in a nucleic acid sequence from a sample |
EP3090063B1 (fr) | 2013-12-31 | 2019-11-06 | Bio-Rad Laboratories, Inc. | Procédé de détection de rétrovirus latent |
US10647981B1 (en) | 2015-09-08 | 2020-05-12 | Bio-Rad Laboratories, Inc. | Nucleic acid library generation methods and compositions |
US20220313616A1 (en) * | 2021-03-30 | 2022-10-06 | Celanese Eva Performance Polymers Llc | Implantable Medical Device for the Delivery of Nucleic Acid-Encapsulated Particles |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0248531A3 (fr) * | 1986-05-02 | 1988-09-28 | Southern Research Institute | Acides nucléiques encapsulés |
US4839111A (en) * | 1987-02-02 | 1989-06-13 | The University Of Tennessee Research Corporation | Preparation of solid core liposomes |
DE69008521T2 (de) * | 1989-03-07 | 1994-10-20 | Genentech Inc | Kovalente konjugate von lipiden und oligonukleotiden. |
-
1994
- 1994-04-19 CA CA002160878A patent/CA2160878A1/fr not_active Abandoned
- 1994-04-19 EP EP94914823A patent/EP0696200A4/fr not_active Withdrawn
- 1994-04-19 WO PCT/US1994/004239 patent/WO1994023738A1/fr not_active Application Discontinuation
- 1994-04-19 NZ NZ265818A patent/NZ265818A/en unknown
- 1994-04-19 AU AU67071/94A patent/AU6707194A/en not_active Abandoned
- 1994-04-19 JP JP6523517A patent/JPH08510639A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO1994023738A1 (fr) | 1994-10-27 |
AU6707194A (en) | 1994-11-08 |
JPH08510639A (ja) | 1996-11-12 |
EP0696200A1 (fr) | 1996-02-14 |
NZ265818A (en) | 1997-09-22 |
EP0696200A4 (fr) | 1998-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2160878A1 (fr) | Encapsulation d'acides nucleiques a l'aide de conjugues qui ciblent et facilitent l'absorption cellulaire et l'expression genique | |
JPH08511418A (ja) | 生分解性極微粒子からのアンチセンスオリゴデオキシリボヌクレオチドの徐放運搬による長期作用のある処置 | |
Perales et al. | An evaluation of receptor‐mediated gene transfer using synthetic DNA‐ligand complexes | |
US6090925A (en) | Macromolecular microparticles and methods of production and use | |
US5981719A (en) | Macromolecular microparticles and methods of production and use | |
US6395253B2 (en) | Microspheres containing condensed polyanionic bioactive agents and methods for their production | |
AU771874B2 (en) | Expandible microparticle intracellular delivery system | |
CA2186118C (fr) | Acides nucleiques compactes et leur distribution aux cellules | |
US20120282343A1 (en) | Compositions for oral gene therapy and methods of using same | |
JP2003535122A (ja) | 生物活性物質のための送達システム | |
US20120058180A1 (en) | Liver-specific Nanocapsules and Methods of Using | |
JP2009261411A (ja) | 核酸を輸送するための微粒子 | |
WO1997030731A2 (fr) | Procede de preparation de complexes porteurs de polynucleotides pour administration a des cellules | |
JP2005511761A (ja) | ナノ粒子送達ビヒクル | |
CN102666879A (zh) | 模板化的纳米缀合物 | |
JPH11510142A (ja) | 核酸負荷ポリマー微粒子を使用した遺伝子治療法 | |
CN101184511A (zh) | 包括由核酸分子和胶原组成的络合物精细颗粒的制剂 | |
CN112639108A (zh) | 治疗非综合征性感觉神经性听力损失的方法 | |
JP2005530695A (ja) | 生理活性物質を細胞内に導入するエレクトロポレーション法 | |
JP2002538198A (ja) | キャリヤー媒介体及びターゲティング媒介体としての細菌ゴースト | |
JP2002509116A (ja) | 核酸およびサイトカインの単一溶媒での同時輸送による遺伝子免疫 | |
JP2003061693A (ja) | ウイルス様粒子、その製造方法およびその使用 | |
JP2011088909A (ja) | 核酸を送達するための微粒子 | |
JP2002508956A (ja) | 遺伝子送達のための方法および組成物 | |
KR100466254B1 (ko) | 세포내 전달을 위한 올리고뉴클레오티드와 친수성 고분자로 구성되는 유전자 전달용 접합체, 고분자 전해질 복합 미셀 및 그의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |